ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
LincNEAT1 Encoded-NEAT1-31 Promotes Phagocytosis by Directly Activating the Aurora-A-PI3K-AKT Pathway.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Proteomic landscape analysis of undifferentiated pleomorphic sarcoma.Genome medicine · 2026Article
- The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies.Cancer cell international · 2025Review
- LincNEAT1 Encoded-NEAT1-31 Promotes Phagocytosis by Directly Activating the Aurora-A-PI3K-AKT Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Macrophages play vital roles in innate and adaptive immunity, and their essential functions are mediated by phagocytosis and antigen presentation. Long non-coding ribonucleic acid nuclear enriched abundant transcript 1 (LincNEAT1) is specifically translated during phagocytosis. Great efforts have been made to explore the potential mechanisms of action of these phagocytic checkpoints. However, the use of a systematic checkpoint scanning strategy has been far from satisfactory, and intrinsic phagocytic activators have not been fully elucidated. Therefore, in vitro phagocytosis assays are performed using primary healthy donor macrophages and breast cancer cells. An equal number of cells are subjected to ribosome profiling, and immune system-specific phagocytic activators are identified. LincNEAT1 and encoded micro peptide NEAT1-31, are considerably upregulated in phagocytic macrophages. Moreover, purified NEAT1-31 promoted the phagocytosis of multiple cancer cell-types. Phosphoproteomic analysis reveals that NEAT1-31 directly promoted Aurora-A activity and activated phosphatidylinositol 3-kinase/protein kinase B signaling. NEAT1-31 enhanced the efficacy of anti-CD47 in vivo and in vitro. Thus, the study identified a novel protein drug that can directly enhance the phagocytic function, thereby providing a new option for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.